News | February 28, 2022
Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Funding to grow the insurance and digital therapeutics vertical in India
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
